ArticleScientific reports2026
Metabolomics-based and functional validation to explore the effect of the gut microbe-associated metabolite guanidinoacetic acid on rectal adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The gut microbiota plays a crucial role in the pathogenesis of rectal adenocarcinoma (READ). While studies have established associations between microbial alterations and READ, the dynamics of gut microbiota-host interactions within this specific disease context remain to be fully elucidated. This study aimed to characterize the structural landscape of the gut microbiota and the profile of faecal metabolites in patients with READ. Faecal samples were collected from 33 individuals with READ and 34 healthy controls (HC), with post-neoadjuvant treatment faecal samples also collected from the 5 READ patients, and 16 S rRNA gene amplification sequencing and untargeted liquid chromatography-mass spectrometry metabolomics analysis were performed. We employed methods such as weighted correlation network analysis (WGCNA) and molecular docking to identify target gene-related information, and performed in vitro experiments to explore the effects of guanidinoacetic acid (GAA) on colorectal cancer cell lines. Bacillota (formerly Firmicutes), Pseudomonadota (formerly Proteobacteria), Actinomycetota (formerly Actinobacteria), and Bacteroidota (formerly Bacteroidetes) were the most abundant phyla in patients with READ and healthy controls (HC). At the genus level, Peptostreptococcus exhibited marked enrichment in the READ cohorts, whereas Faecalibacterium was dominant in the HC group. The predicted microbial functional analysis indicated a significant increase in the metabolism of betaine, guanidinoacetic acid (GAA), L-tryptophan, arachidonic acid, and arachidic acid. Moreover, by comparing the faecal metabolites between the HC and READ groups, Pearson's correlation analysis demonstrated significant interactions between six microbiota taxa and nine metabolites, suggesting specific human metabolic pathways. The cellular function results demonstrated that GAA promoted the proliferation, invasion, and migration of colorectal cells while inhibiting apoptosis. Further analysis revealed that GAA may promote CRC progression of colorectal cancer by affecting molecules such as KLB, CA2, CSTG, CYP4F12, and GZBM. Through integrated analysis, this study links gut microbial metabolites to READ and identifies GAA as a metabolite with possible relevance to the disease process, indicating a direction for further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.